Concepedia

Publication | Open Access

A Phase I and Pharmacological Study with Imidazolium-<b> <i>trans-</i> </b>DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

DOIFull Paper Access

820

Citations

22

References

2004

Year

Jeany M. Rademaker-Lakhai, H.J.G.D. van den Bongard, Dick Pluim, Jos H. Beijnen, Jan H.M. Schellens
Clinical Cancer Research

Abstract

NAMI-A can be administered safely as a 3-h i.v. infusion at a dose of 300 mg/m(2)/day for 5 days, every 3 weeks.

References

YearCitations

Page 1